<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03827759</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL18_0293</org_study_id>
    <secondary_id>7683</secondary_id>
    <nct_id>NCT03827759</nct_id>
  </id_info>
  <brief_title>Differentiate Children Septic and Inflammatory Arthritis by Comparative Analysis</brief_title>
  <acronym>DIANE</acronym>
  <official_title>Multicenter, Diagnostic and Prospective Study to Differentiate Child Septic and Inflammatory Arthritis by Comparative Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to found new biomarker that differentiate septic arthritis and Juvenile&#xD;
      Idiopathic Arthritis in children. Synovial liquid and blood samples with proteomic, MiRNA&#xD;
      searching, multiplex cytokine analysis and cellular phenotyping, will be analysed. The&#xD;
      results for each data will be compared in function of the disease to search discriminant&#xD;
      markers. On behalf with this result specific pathways could be identified .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This a multicentric prospective study that compares biological fluids as synovial liquid and&#xD;
      blood samples to find biomarkers that could distinguish septic arthritis and juvenile&#xD;
      idiopathic arthritis. Prospectively, patients will be recruited under the age of 15 who are&#xD;
      in care for septic or inflammatory arthritis at the University Hospitals of Montpellier,&#xD;
      Lyon, Nimes and Toulouse. Patients should have an indication of blood and synovial as part of&#xD;
      their management :&#xD;
&#xD;
      Group A: acute juvenile arthritis with suspicion of bacterial infection, , confirmed on a&#xD;
      bacteriological plan, either by culture of the articular liquid or by blood culture, or by&#xD;
      molecular biology in the articular liquid.&#xD;
&#xD;
      Group B: Idiopathic juvenile arthritis and control topics (Group C). In this project, the aim&#xD;
      is to analyze all in all 30 articular liquids and serum of inflammatory arthritises (Group&#xD;
      B), and 30 articular liquids and serum of infectious confirmed arthritises (Group A) which&#xD;
      will require the inclusion about 50 possibly septic arthritis. The diagnosis of infectious&#xD;
      arthritis is not immediate, he(it) is confirmed at the latest three weeks after the draining.&#xD;
      So a group of control will be constituted.&#xD;
&#xD;
      Group C: the blood of 10 healthy children matched by the age and at the sex in the groups A&#xD;
      and B will be collected to analyze elements studied in the blood.&#xD;
&#xD;
        -  Inclusion criteria :&#xD;
&#xD;
      Group A and group B:&#xD;
&#xD;
        -  Subject of more than 6 months and under age 15 years,&#xD;
&#xD;
        -  Presenting acute arthritis taken care in the University Hospitals of Montpellier, Nimes,&#xD;
           Toulouse or Lyon, and requiring an articular puncture&#xD;
&#xD;
        -  Child benefiting from a social security system,&#xD;
&#xD;
        -  Collection of the consent of the legal parents/representatives,&#xD;
&#xD;
      Group C:&#xD;
&#xD;
        -  Subject of more than 6 months and under age 15 include&#xD;
&#xD;
        -  Taken care in the University Hospital of Montpellier, and requiring a venous draining,&#xD;
&#xD;
        -  Child benefiting from a social security system,&#xD;
&#xD;
        -  Collection of the consent of the legal parents/representatives&#xD;
&#xD;
             -  Non inclusion criteria /&#xD;
&#xD;
      Group A and group B:&#xD;
&#xD;
        -  Contraindication in an articular draining: platelet 50 000/mm3, pathologic hemostasis&#xD;
&#xD;
        -  Treatment by biological therapy, corticoids or other immunosuppressant treatment in the&#xD;
           month preceding the articular draining,&#xD;
&#xD;
        -  antibiotic begun more than 24 hours before the inclusion.&#xD;
&#xD;
      Group C: ·&#xD;
&#xD;
        -  Patient achieves of an inflammatory chronic pathology&#xD;
&#xD;
        -  Patient having presented an infectious episode in the previous 8 days -Patients under&#xD;
           immunosuppressor or anti-infective&#xD;
&#xD;
      Methods of measure of assessment criteria&#xD;
&#xD;
      Analysis will be done on blood samples and synovial liquid, that remains after sample&#xD;
      collected for the management of their disease. The blood test and an synovial liquid draining&#xD;
      will be realized at the subject. Before freezing, aliquots will be realized so that every&#xD;
      analysis can benefit from a minimum volume:&#xD;
&#xD;
        -  Cellular analyses: will be only made in Montpellier and established by the set of&#xD;
           collected cells (no necessary volume).&#xD;
&#xD;
        -  Proteomic, MiRNA analysis and cytokine dosing will been done in the second time.&#xD;
&#xD;
      Statistical analysis will be done to individualize biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Qualitative analysis of new biological markers (proteic) that discriminate inflammatory and infectious arthritis</measure>
    <time_frame>1 day</time_frame>
    <description>Identify blood sampling proteic markers of Arthritis childhood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Qualitative analysis of new biological markers (cytokine) that discriminate inflammatory and infectious arthritis</measure>
    <time_frame>1 day</time_frame>
    <description>Identify blood sampling markers (cytokine : interleukin 2, interleukin 4, interleukin 6, interleukin 7, tumor necrosis factor alpha (TNF)) of Arthritis childhood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Qualitative analysis of new cellular markers that discriminate inflammatory and infectious arthritis</measure>
    <time_frame>1 day</time_frame>
    <description>Identify blood sampling cellular markers (lymphocytes and monocytes) of Arthritis childhood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Qualitative analysis of inflammatory process markers</measure>
    <time_frame>1 day</time_frame>
    <description>Identify articular liquid sampling biomarkers (lymphocytes and interleukins) of Arthritis childhood</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Septic Arthritis</condition>
  <condition>Inflammatory Arthritis</condition>
  <condition>Children</condition>
  <arm_group>
    <arm_group_label>septic arthritis (group A)</arm_group_label>
    <description>Patients with acute juvenile arthritis with suspicion of bacterial infection,confirmed on a bacteriological plan, either by culture of the articular liquid or by blood culture, or by molecular biology in the articular liquid;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inflammatory arthritis (group B)</arm_group_label>
    <description>Patients with idiopathic juvenile arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control (group C)</arm_group_label>
    <description>10 healthy children who are matched by the age and at the sex in the groups A and B, to analyze elements studied in the blood.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Synovial liquid and blood samples (with : proteomic, MiRNA searching, multiplex cytokine&#xD;
      analysis and cellular phenotyping) will be analysed.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects of more than 6 months and under age 15 years, presenting acute arthritis, and&#xD;
        control subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group A and group B:&#xD;
&#xD;
          -  Subject of more than 6 months and under age 15 years,&#xD;
&#xD;
          -  Presenting acute arthritis taken care in the University Hospitals of Montpellier,&#xD;
             Nimes, Toulouse or Lyon, and requiring an articular puncture,&#xD;
&#xD;
          -  Child benefiting from a social security system,&#xD;
&#xD;
          -  Collection of the consent of the legal parents/representatives,&#xD;
&#xD;
        Group C:&#xD;
&#xD;
          -  Subject of more than 6 months and under age 15 include,&#xD;
&#xD;
          -  Taken care in the University Hospital of Montpellier, and requiring a venous draining,&#xD;
&#xD;
          -  Child benefiting from a social security system,&#xD;
&#xD;
          -  Collection of the consent of the legal parents/representatives&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Group A and group B:&#xD;
&#xD;
          -  Contraindication in an articular draining: platelet 50 000/mm3, pathologic hemostasis&#xD;
&#xD;
          -  Treatment by biological therapy, corticoids or other immunosuppressant treatment in&#xD;
             the month preceding the articular draining,&#xD;
&#xD;
          -  antibiotic begun more than 24 hours before the inclusion.&#xD;
&#xD;
        Group C:&#xD;
&#xD;
          -  Patient achieves of an inflammatory chronic pathology&#xD;
&#xD;
          -  Patient having presented an infectious episode in the previous 8 days&#xD;
&#xD;
          -  Patients under immunosuppressor or anti-infective&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric JEZIORSKI, MD PhD</last_name>
    <phone>+334.67.33.67.33</phone>
    <email>e-jeziorski@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hugues CHEVASSUS, PharmD</last_name>
    <email>h-chevassus@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Montpellier - Pediatric emergencies</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric JEZIORSKI, MD PhD</last_name>
      <phone>+334.67.33.67.33</phone>
      <email>e-jeziorski@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Eric JEZIORSKI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Djamel LOUAHEM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme COTTALORDA, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - pediatric rheumatology</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey LAURENT, MD</last_name>
      <email>audrey.laurent@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Audrey LAURENT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre BELOT, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marine FOUQUET-DESJONQUERES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte REBEL, MD</last_name>
      <phone>04 91 80 82 92</phone>
      <email>crebelle@hopital-saint-joseph.fr</email>
    </contact>
    <investigator>
      <last_name>Charlotte REBEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie SAUVAGET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes - Pediatrics</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tu Ahn TRAN, MD</last_name>
      <phone>+334.66.68.32.84</phone>
      <email>tu.anh.tran@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Tu Ahn TRAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Pediatric infectious diseases</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille BREHIN, MD</last_name>
      <phone>+335.34.55.84.20</phone>
      <email>brehin.c@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Jérôme SALES DE GAUZY, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine AUDOUIN PAJOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile GUILLOU-DEBUISSON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille BREHIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>idiopathic juvenile arthritis, septic arthritis, biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Infectious</mesh_term>
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

